Outcome after relapse in childhood acute lymphoblastic leukemia

International Journal of Hematology

Volumn 76, Issue 1, 2002, Pages 61-68

  Yumura Yagi, Keiko ^a   Hara, Junichi ^b   Horibe, Keizo ^c   Tawa, Akio ^d   Komada, Yoshihiro ^e   Oda, Megumi ^f   Nishimura, Shinichiro ^g   Yoshida, Makoto ^h   Kudo, Tooru ⁱ   Ueda, Kazuhiro ^g  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^h ASAHIKAWA MEDICAL COLLEGE   (Japan)

ⁱ SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute lymphoblastic leukemia; Children; Relapse; Stem cell transplantation

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; RECURRENT DISEASE; SURVIVAL RATE; ACUTE LYMPHOCYTIC LEUKEMIA; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MULTICENTER STUDY; PHENOTYPE; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JAPAN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; MULTICENTER STUDIES; PHENOTYPE; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036632999     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982720     Document Type: Article

References (27)

1. Pui C-H, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
2. Horibe K, Hara J, Yagi K, et al. Prognostic factors in childhood acute lymphoblastic leukemia in Japan: Japan Association of Childhood Leukemia Study. Int J Hematol. 2000;72:61-68.
3. Chessells JM. Relapsed lymphoblastic leukemia in children: a continuing challenge. Br J Haematol. 1998;102:423-438.
4. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
5. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia. Cancer. 1998;82:1387-1395.
6. Henze G, Fengler R, Hartman R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): a relapse study of the BFM group. Blood. 1991;78:1166-1172.
7. Buchanan GR, Rivera GK, Pollock BH, et al. Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission. Cancer. 2000;88:1166-1174.
8. Lawson SE, Harrison G, Richards S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukemia: a report on the Medical Research Council UKALLR1 study. Br J Haematol. 2000;108:531-543.
9. Beyermann B, Adams H-P, Henze G. Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia: a matched-pair analysis. J Clin Oncol. 1997;15:2231-2237.
10. Uderzo C, Valsecchi MG, Bacigalupo A, et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Pediatric Hematology Oncology Association. J Clin Oncol. 1995;13:352-358.
11. Feig SA, Harris RE, Sather HN. Bone marrow transplantation versus chemotherapy for maintenance of second remission of childhood acute lymphoblastic leukemia: a study of the Children's Cancer Group (CCG-1884). Med Pediatr Oncol. 1997;29:534-540.
12. Wheeler K, Richards S, Balley C, Chessels J. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukemia: the MRC UKALL X experience: Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol. 1998;101:94-103.
13. Schroeder H, Gustafsson G, Saarinen-Pihkala UM, et al. Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries. Bone Marrow Transplant. 1999;23:555-560.
14. Boulad F, Steinherz P, Reyes B, et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol. 1999;17:197-207.
15. Barrett J, Horowitz MM, Pollock BH, et al. Bone marrow transplantation from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med. 1994;331:1253-1258.
16. Buhrer C, Hartmann R, Fengler R, et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome: Berlin-Frankfurt-Munster Relapse Study Group. J Clin Oncol. 1996;14:2812-2817.
17. Rivera GK, Hudson MM, Liu Q, et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood. 1996;88:831-837.
18. Gustafsson A, Remberger M, Winiarski J, et al. Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting. Bone Marrow Transplant. 2000;25:1059-1065.
19. Vaidya SJ, Atra A, Bahl S, et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: long-term follow-up. Bone Marrow Transplant. 2000;25:599-603.
20. Maldonado MS, Diaz-Heredia C, Badell I, et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for children with acute lymphoblastic leukemia in second remission. Bone Marrow Transplant. 1998;22:1043-1047.
21. Wesdorf DJ, Billett AL, Hannan P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood. 1997;90:2962-2968.
22. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia: European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591-598.
23. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691-2696.
24. Pui C-H, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
25. Schrappe M, Reiter A, Ludwig W-D, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310-3322.
26. Ribeiro RC, Rivera GK, Hudson M, et al. An intensive re-treatment protocol for children with isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol. 1995;13:333-338.
27. Belasco JB, Goldwein JW, Simms S, Griffin G, D'Angio G, Lange B. Hyperfractionated moderate dose radiation, intrathecal chemotherapy, and repetitive reinduction/reconsolidation systemic therapy for central nervous system relapse of acute lymphoblastic leukemia in children. Med Pediatr Oncol. 2000;34:125-131.